Last updated: February 19, 2026
This report analyzes the patent litigation between Array BioPharma, Inc. and Alembic Pharmaceuticals Limited, focusing on U.S. District Court for the District of Delaware case number 1:22-cv-01277. The dispute centers on Alembic's proposed generic version of Array's BRAFTOVI® (encorafenib).
What Patents Are in Dispute?
The litigation involves three United States patents owned by Array BioPharma, Inc. These patents cover crystalline forms of encorafenib and methods of treating certain cancers.
- U.S. Patent No. 9,713,481: This patent claims crystalline forms of encorafenib. Specifically, it covers Form A and Form B.
- U.S. Patent No. 10,125,021: This patent also claims crystalline forms of encorafenib, including a specific polymorphic form designated as Form C.
- U.S. Patent No. 10,603,450: This patent claims methods of treating BRAF V600E mutant melanoma using encorafenib.
Alembic Pharmaceuticals Limited seeks to market a generic version of BRAFTOVI®. Array alleges that Alembic's proposed product infringes on these patents.
What is Alembic's Defense Strategy?
Alembic's primary defense strategy involves challenging the validity and enforceability of Array's asserted patents. This typically includes arguments of:
- Invalidity: Alembic argues that the asserted claims of the '481, '021, and '450 patents are invalid. Grounds for invalidity often include:
- Obviousness: The claimed inventions would have been obvious to a person of ordinary skill in the art at the time the invention was made, in light of prior art.
- Lack of Enablement: The patent specification does not describe how to make and use the claimed invention in a manner that is commensurate with the scope of the claims.
- Lack of Written Description: The patent specification does not clearly convey that the inventor was in possession of the claimed invention.
- Non-infringement: Alembic contends that its proposed generic product does not fall within the scope of the claims of Array's asserted patents.
What is the Status of the Litigation?
As of the most recent available filings, the litigation is in its early stages, typically involving claim construction (Markman hearings) and potentially discovery.
- Initial Filings: Array BioPharma filed its complaint on August 10, 2022. Alembic filed its answer and counterclaims on October 3, 2022.
- Claim Construction: The court will likely conduct a Markman hearing to construe the disputed patent claims. This is a critical phase that defines the scope of the patents and can significantly impact the infringement analysis. The court's claim construction order will guide subsequent proceedings.
- Discovery: Parties will engage in discovery, exchanging documents, interrogatories, and potentially taking depositions to gather evidence supporting their respective positions on validity and infringement.
What is the Commercial Significance of BRAFTOVI®?
BRAFTOVI®, in combination with MEKTOVI® (binimetinib), is approved for treating patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It also has an indication for metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The market for BRAF inhibitors is substantial, driven by the prevalence of these specific mutations in melanoma and NSCLC.
Array BioPharma was acquired by Pfizer in July 2019, and Pfizer now manages the BRAFTOVI® and MEKTOVI® portfolio. The commercial success of these drugs makes them a target for generic manufacturers seeking to enter the market upon patent expiry or successful patent challenges.
What are the Key Legal Issues?
The core legal issues revolve around patent validity and infringement.
Patent Validity
Alembic's arguments for invalidity will likely focus on the state of the art concerning BRAF inhibitors and crystalline forms of small molecules prior to Array's patent filings.
- Prior Art for Crystalline Forms: For U.S. Patent Nos. 9,713,481 and 10,125,021, Alembic will investigate prior art disclosures of encorafenib or similar compounds, looking for evidence of known crystalline forms or methods that would render the claimed forms obvious. The patentability of crystalline forms often depends on whether the claimed form possesses unexpected properties (e.g., improved stability, bioavailability, or manufacturability) compared to known forms.
- Prior Art for Method of Treatment: For U.S. Patent No. 10,603,450, Alembic will examine prior art related to BRAF V600E mutations and the treatment of melanoma. The key inquiry will be whether the specific combination and dosage regimen taught by Array were obvious to a skilled person in light of existing knowledge about BRAF inhibitors and melanoma treatment.
Patent Infringement
Array will need to demonstrate that Alembic's proposed generic product infringes the asserted patent claims.
- Direct Infringement: If Alembic's proposed drug product contains or is made using a process covered by an Array patent claim, it constitutes direct infringement. For the crystalline form patents, this would involve showing that Alembic's product uses the patented crystalline form. For the method of treatment patent, it would involve demonstrating that doctors or patients using Alembic's drug for the patented indication would constitute infringement.
- Inducement and Contributory Infringement: Array may also pursue claims of induced or contributory infringement if Alembic's actions encourage or contribute to infringing acts by others.
What is the Timeline for Resolution?
Patent litigation in the pharmaceutical sector is often protracted.
- Markman Hearing and Order: Typically occurs 6-12 months after the initial complaint.
- Discovery: Can last 12-18 months.
- Trial: If the case proceeds to trial, it could be scheduled 18-36 months from the filing date, depending on court dockets and pre-trial motions.
- Appeals: Post-trial appeals can add an additional 12-24 months to the resolution timeline.
Given the filing date of August 10, 2022, a resolution through trial and potential appeal could extend into 2025-2028. However, settlements are common and can occur at any stage.
What are the Potential Outcomes?
The potential outcomes of this litigation include:
- Infringement Finding: The court finds that Alembic's product infringes one or more of Array's patents. This could lead to an injunction preventing Alembic from launching its generic product until the patents expire or are otherwise invalidated.
- Invalidity Finding: The court finds one or more of Array's patents invalid. This would remove the patent protection for that specific patent, potentially allowing Alembic to launch its generic product earlier.
- Non-Infringement Finding: The court finds that Alembic's product does not infringe Array's patents. This would also allow Alembic to proceed with its launch.
- Settlement: The parties reach a confidential agreement to resolve the dispute. This often involves a licensing agreement for the generic product, allowing for a controlled market entry by the generic manufacturer.
- Partial Victory: The court might find some patents valid and infringed, while others are invalid or not infringed, leading to a complex outcome that may still impact market entry.
Key Takeaways
- The litigation involves three key patents for BRAFTOVI® (encorafenib): two covering specific crystalline forms and one covering a method of treatment for melanoma.
- Alembic Pharmaceuticals aims to invalidate Array's patents through arguments of obviousness, lack of enablement, and lack of written description.
- The dispute's resolution hinges on the court's claim construction and findings on patent validity and infringement.
- Given the complexity and typical duration of pharmaceutical patent litigation, resolution is not expected for at least 18-36 months, with appeals potentially extending the timeline further.
- A favorable outcome for Array would block or delay Alembic's generic entry, preserving BRAFTOVI®'s market exclusivity. Conversely, a victory for Alembic could open the market to generic competition sooner.
Frequently Asked Questions
1. Which specific crystalline forms of encorafenib are claimed in U.S. Patent Nos. 9,713,481 and 10,125,021?
U.S. Patent No. 9,713,481 claims crystalline forms designated as Form A and Form B. U.S. Patent No. 10,125,021 claims a specific polymorphic form designated as Form C.
2. What is the primary indication covered by U.S. Patent No. 10,603,450?
U.S. Patent No. 10,603,450 claims methods of treating BRAF V600E mutant melanoma using encorafenib.
3. When did Array BioPharma file its initial complaint in this litigation?
Array BioPharma filed its complaint on August 10, 2022.
4. What is the significance of a Markman hearing in this case?
A Markman hearing is crucial for determining the meaning and scope of the disputed patent claims. The court's claim construction order will define the boundaries of the patents, significantly impacting the subsequent analysis of whether Alembic's product infringes those claims.
5. Has Pfizer acquired Array BioPharma, and does this impact the litigation?
Yes, Pfizer acquired Array BioPharma in July 2019. Pfizer is now the owner and manager of the BRAFTOVI® and MEKTOVI® portfolio, and therefore controls this patent litigation.
Citations
[1] United States District Court, District of Delaware. (2022, August 10). Complaint for Patent Infringement. Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited, et al. Case No. 1:22-cv-01277.
[2] United States District Court, District of Delaware. (2022, October 3). Answer and Counterclaims. Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited, et al. Case No. 1:22-cv-01277.
[3] U.S. Patent No. 9,713,481. (2017). Crystalline forms of encoranfenib. Array BioPharma, Inc.
[4] U.S. Patent No. 10,125,021. (2019). Crystalline forms of encoranfenib. Array BioPharma, Inc.
[5] U.S. Patent No. 10,603,450. (2020). Methods of treating melanoma. Array BioPharma, Inc.
[6] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA.gov website] (Specific drug approval pages for BRAFTOVI® and MEKTOVI® would be cited here if publicly accessible and directly used for commercial data).
[7] Pfizer Inc. (2019, July 26). Pfizer Completes Acquisition of Array BioPharma. [Press Release].
